- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04359602
COVID-19 Recovered Volunteer Research Participant Pool Registry
December 22, 2025 updated by: University of California, Los Angeles
This is a prospective observational registry of COVID-19 recovered patients who are no longer symptomatic.
This Registry is intended to serve as a pool of individuals that can participate in studies associated with serological testing, characterization of immunity and immune response, vaccine development, and convalescent plasma donors.
Study Overview
Status
Active, not recruiting
Conditions
Study Type
Observational
Enrollment (Actual)
5090
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Ronald Reagan UCLA Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
People volunteering to share their information to become part of this research pool of COVID-19 recovered individuals will complete an online survey.
Description
Inclusion Criteria:
All patients seen the in emergency room, admitted patients, or seen in outpatient clinics that are:
- Tested Positive for COVID-19 and recovered
- Suspected to have COVID 19 and validated with serological testing
- Suspected to have COVID 19 by symptoms, clinical course, and laboratory testing ruling out other respiratory viral disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serological testing of COVID patients
Time Frame: Up to 20 years
|
Testing may be done on registry participants who agree to participate future studies
|
Up to 20 years
|
|
Immune response
Time Frame: Up to 20 years
|
Testing may be done on registry participants who agree to participate future studies
|
Up to 20 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Arash Naeim, MD, PhD, University of California, Los Angeles
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 8, 2020
Primary Completion (Actual)
September 29, 2021
Study Completion (Estimated)
April 20, 2042
Study Registration Dates
First Submitted
April 21, 2020
First Submitted That Met QC Criteria
April 22, 2020
First Posted (Actual)
April 24, 2020
Study Record Updates
Last Update Posted (Estimated)
December 23, 2025
Last Update Submitted That Met QC Criteria
December 22, 2025
Last Verified
December 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-000625
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recovered From COVID-19
-
TScan Therapeutics, Inc.CompletedIdentify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection | Determine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA TypesUnited States
-
B.P. Koirala Institute of Health SciencesCompletedProximal Humerus Surgery in Covid Recovered PatientsNepal
-
Larissa University HospitalRecruitingRespiratory Disease (Clinically Stable Individuals - Patients Recovered From Respiratory Disease)Greece
-
Assiut UniversityDoaa M.EL ShehabyUnknownCovid 19 Pandemic From Ethical View
-
Gangnam Severance HospitalWithdrawnContact Person From COVID-19 Confirmed PatientKorea, Republic of
-
Western Sussex Hospitals NHS TrustCompletedExploring Risk Assessment and Recovery From COVID-19 Infection in Hospitalised PatientsUnited Kingdom
-
PfizerActive, not recruitingCOVID-19 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | COVID-19 Vaccines | SARS-CoV-2 Infection, COVID19 | COVID-19 Vaccination | SARS-CoV-2 Infection, COVID-19 | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionUnited States
-
Federal State Budgetary Scientific Institution...CompletedThermal Condition of Health Workers Who Use Personal Protective Equipment From Biological Hazards During Their Work With COVID-19 PatientsRussian Federation
-
Shanghai Public Health Clinical CenterNot yet recruiting
-
Duke UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Completed